Steve Schonfeld’s Nektar Therapeutics NKTR Stock Holding History

Steve Schonfeld’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,667	Closed	-$1.8M	–	2409
2021 Q3	$1.8M	Buy	+6,667	New	+$1.6M	0.02%	752

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's NKTR Position: Q2 2026 in Review

Steve Schonfeld sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 8,063 shares — an estimated $580K sold.

Steve Schonfeld first reported a position in NKTR in Q3 2016 and held it in 18 quarters. The position peaked at $2.62M in Q2 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Steve Schonfeld reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 8,063 Nektar Therapeutics shares in Q2 2026, an estimated $580K.
Steve Schonfeld first reported a position in Nektar Therapeutics in Q3 2016 and held it in 18 quarters.
Steve Schonfeld's Nektar Therapeutics position peaked at $2.62M in Q2 2025.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.